Cutaneous Lupus: Risk of Systemic Progression and a Rapidly Expanding Targeted Therapy Pipeline
Joseph F. Merola, MD, MMSc, FAAD, FACR, delivered an energizing and forward-looking session on cutaneous and systemic lupus considerations at the 2026 Masterclasses in Dermatology Annual Meeting. His message to dermatologists was both reassuring and ambitious: “Dermatologists must treat CLE—it’s our disease.”
He added, “Dermatologists should not fear SLE” and perhaps most importantly, “dermatologists should embrace new therapies for CLE/SLE” and be “very excited about the pipeline.”
Dr Merola reviewed the major subtypes of cutaneous lupus erythematosus (CLE), including discoid lupus erythematosus (DLE), subacute cutaneous lupus (SCLE), and generalized or drug-induced variants. Up to 30% of CLE overlaps with systemic lupus erythematosus (SLE).
Progression risk from DLE to SLE is real but time dependent. In the Brigham and Women’s Hospital lupus registry, most patients who progressed did so within 1 to 2 years of DLE diagnosis, with a median time to progression of 453 days. This underscores the need for structured monitoring.
SCLE is strongly associated with anti-Ro/SSA antibodies (70%–90%) and photosensitivity. Drug-induced SCLE may present with more widespread distribution (OR 66.1) and vasculitic features (OR 32), and anti-Ro/SSA antibodies disappear after resolution in 73% of cases. Common triggers include HCTZ, calcium channel blockers, ACE inhibitors, statins, proton pump inhibitors, terbinafine, and certain oncologic agents.
Therapeutically, the interferon pathway has transformed SLE management. Anifrolumab, a type I interferon receptor antagonist approved for SLE, demonstrated early and sustained reduction in skin disease severity in pooled TULIP-1 and TULIP-2 data, with ≥50% Cutaneous Lupus Erythematosus Disease Area and Severity Index-A (CLASI-A) improvement among patients with baseline CLASI-A ≥10. Rapid cutaneous responses have been reported after a single dose.
Next, Dr Merola shed light on litifilimab, a BCDA2 inhibitor representing another mechanistic advance. Litifilimab (BIIB059) targets plasmacytoid dendritic cells and type I interferon production. In a 132-subject trial of CLE ± SLE, significant CLASI improvements were observed at 16 weeks.
Deucravacitinib, a TYK2 inhibitor, is emerging as well. In the PAISLEY CLE study, deucravacitinib demonstrated significant CLASI-50 and CLASI-70 responses at week 16. In SLE cohorts, sustained CLASI responses were seen at 48 weeks.
Oral enpatoran, a dual TLR7/8 inhibitor, showed a significant dose-response reduction in CLASI-A by week 16, with up to 87% achieving CLASI-50 at week 24 in exploratory analyses. “This is phase 2 data and phase 3 data will be coming soon,” Dr Merola remarked.
Dr Merola emphasized practical co-management. In patients with CLE plus arthritis, nephritis, interstitial lung disease, or antiphospholipid antibodies, therapy selection must align with systemic features. He reinforced the importance of facilitated communication between dermatology and rheumatology. “The future is bright for continuous lupus,” he concluded.
For more meeting coverage, visit the Masterclasses in Dermatology newsroom.
Reference
Merola J. Cutaneous and systemic lupus considerations. Presented at: Masterclasses in Dermatology; February 19–22, 2026; Sarasota, FL.
